Table 2.
Clinical Characteristics of Proband and Relative Groups
| Probands | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sczb (N = 274) | SczAc (N = 164) | BPd (N = 222) | ||||||
| Medication Treatment | N (%) | N (%) | N (%) | Post hoc† | ||||
| First Gen. Antipsychotic | 34 (12.4) | 16 (9.7) | 13 (5.9) | b>d | ||||
| Second Gen. Antipsychotic | 214 (78.1) | 129 (77.7) | 148 (66.7) | b,c>d | ||||
| Mood Stabilizer | 40 (14.6) | 73 (44.5) | 101 (45.5) | b<c,d | ||||
| Lithium | 15 (5.5) | 16 (9.8) | 56 (25.2) | b,c<d | ||||
| Antidepressant | 106 (38.7) | 93 (56.7) | 97 (43.7) | b,d<c | ||||
| Stimulant | 13 (4.7) | 8 (4.9) | 25 (11.3) | b,c<d | ||||
| Sedative/ Hypnotic | 58 (21.7) | 50 (30.5) | 72 (32.4) | b<d | ||||
| Anticholinergic | 50 (18.2) | 21 (12.8) | 21 (9.5) | b>d | ||||
| Probands | ||||||||
| Sczb (N = 274) | SczAc (N = 164) | BPd (N = 222) | ||||||
| Clinical symptom ratings | Mean (SD) | Mean (SD) | Mean (SD) | Post hoc† | ||||
| PANSS | ||||||||
| Positive | 16.6 (5.6) | 17.9 (5.2) | 12.7 (4.4) | b>d; c>b,d | ||||
| Negative | 16.5 (5.8) | 16.1 (5.2) | 11.9 (3.9) | b,c>d | ||||
| Total | 65.1 (17.0) | 68.8 (15.9) | 53.0 (13.8) | b,c>d | ||||
| YMRS | 5.5 (5.7) | 7.1 (6.4) | 5.6 (6.4) | b<c | ||||
| MADRS | 8.3 (7.9) | 14.7 (10.2) | 9.7 (9.1) | c>b,d | ||||
| Relatives | ||||||||
| Scze (N = 303) | SczAf (N = 187) | BPg (N = 251) | ||||||
| Clinically affected relatives | N (%) | N (%) | N (%) | Post hoc† | ||||
| Psychotic disorders | 34 (11.2) | 27 (14.4) | 22 (8.8) | — | ||||
| Elevated psychosis spectrum personality traits | 40 (13.2) | 25 (13.3) | 30 (12.0) | — | ||||
Note: PANSS, Positive and Negative Syndrome Scale; MADRS, Montgomery Asberg Depression Rating Scale.
†Hochberg test for post hoc comparison from univariate analysis for continuous variables; Z-test for post hoc comparison from chi-square analysis for categorical variables.